pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharma Germany is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypophosphatasia, Paroxysmal Nocturnal Hemoglobinuria, Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
Approved · small molecule · HYPOPHOSPHATASIA
Asfotase alfa (STRENSIQ) is a recombinant alkaline phosphatase enzyme replacement therapy developed by Alexion Europe SAS for the treatment of hypophosphatasia, a rare genetic disorder characterized by deficiency of alkaline phosphatase activity. The drug is administered by subcutaneous or intravenous injection and wor
Internal code AA-HPP-407
Asfotase alfa (STRENSIQ) is a recombinant alkaline phosphatase enzyme replacement therapy developed by Alexion Europe SAS for the treatment of hypophosphatasia, a rare genetic disorder characterized by deficiency of alkaline phosphatase activity. The drug is administered by subcutaneous or intravenous injection and works by replacing the deficient enzyme, thereby restoring normal bone mineralization and metabolic function. STRENSIQ has achieved regulatory approval across major markets including the European Union (approved February 2026), Japan (approved July 2015), and the United States (BLA 125513). The current development focus centers on the RESTORE trial (NCT 2022-502793-17-00), an open-label prospective study investigating immunosuppressive therapies to mitigate immune-mediated loss of therapeutic response to asfotase alfa. This represents a strategic effort to address a known clinical challenge in long-term enzyme replacement therapy: the development of neutralizing antibodies that can reduce drug efficacy. The program remains active with ongoing clinical investigation into optimizing treatment durability and patient outcomes in hypophosphatasia.
Hypophosphatasia is a rare inherited metabolic disorder with significant unmet medical need. The disease results from mutations in the alkaline phosphatase gene (ALPL), leading to defective bone mineralization, dental abnormalities, and in severe cases, respiratory compromise and early mortality. The patient population is small but clinically vulnerable, with severe forms presenting in infancy and childhood. Prior to asfotase alfa approval, treatment options were limited to symptomatic management, making this enzyme replacement therapy a clinically meaningful advance. The competitive landscape includes other rare disease therapeutics such as SEPHIENCE (PTC Therapeutics), PALYNZIQ (BioMarin), REPLAGAL (Takeda), and MEPSEVII (Ultragenyx), reflecting the broader rare metabolic disease market. Asfotase alfa's market relevance is anchored in its disease-modifying potential and ability to improve bone health outcomes in a previously untreatable population. The RESTORE trial's focus on antibody-mediated loss of response addresses a critical clinical problem that can limit long-term therapeutic benefit, positioning improved immunological management as a key commercial and clinical differentiator. Success in mitigating immune responses could extend treatment durability and expand the addressable patient population.
Drug Class: Recombinant alkaline phosphatase enzyme replacement therapy
Modality: Protein/biologic (classified as small_molecule in database, though mechanistically a recombinant enzyme)
Route of Administration: Injection (subcutaneous or intravenous)
Therapeutic Classification: Alimentary tract and metabolism (ATC A16)
Mechanism of Action: Asfotase alfa is a recombinant human alkaline phosphatase that replaces the deficient enzyme in hypophosphatasia, restoring the enzymatic capacity to hydrolyze inorganic pyrophosphate and pyridoxal-5-phosphate, thereby normalizing bone mineralization and reducing metabolic complications.
Related Therapies: Other enzyme replacement therapies and rare metabolic disease treatments in the competitive set include REPLAGAL (idursulfase, Takeda), ELAPRASE (idursulfase, Takeda), VIMIZIM (galipase, BioMarin), NAGLAZYME (galsulfase, BioMarin), BRINEURA (cerliponase alfa, BioMarin), and MEPSEVII (vestronidase alfa, Ultragenyx).
First Approval: Japan (July 2015); subsequently approved in the United States and European Union.
Also known as: HPP, Rathburn disease, deficiency of alkaline phosphatase (disorder) [ambiguous], phosphoethanolaminuria, childhood hypophosphatasia, hypophospatasia, childhood
Prevalence: Point prevalence: <1 / 1 000 000 (China) — source: Orphanet, validated.
Hypophosphatasia (HPP) is a rare heritable metabolic disorder characterized by defective mineralization of bone and/or teeth in the presence of reduced activity of unfractionated serum alkaline phosphatase (ALP). The clinical spectrum is extremely wide, from stillbirth at one end to fractures of the lower extremities in adulthood, at the other, or even no bone manifestations (odontohypophosphatasia).
ClinicalTrials.gov lists 34 registered studies for Hypophosphatasia (AACT aggregate).
Phase breakdown: NA (19), PHASE2 (6), PHASE3 (3), PHASE4 (3), PHASE1 (1), PHASE1/PHASE2 (1), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018570), Orphanet — hypophosphatasia, NCT00894075, NCT01163149, NCT01176266, NCT01205152, NCT01406977, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Japan approval
Asfotase alfa approved in Japan for hypophosphatasia treatment.
European Union approval
European Medicines Agency grants marketing authorization for STRENSIQ (EMEA/H/C/003794).
RESTORE trial ongoing
Open-label prospective study (NCT 2022-502793-17-00) investigating immunosuppressive therapies to mitigate immune-mediated loss of therapeutic response to asfotase alfa.
The rare metabolic disease market includes multiple approved enzyme replacement and substrate reduction therapies. SEPHIENCE (PTC Therapeutics) and PALYNZIQ (BioMarin) target phenylketonuria and related metabolic disorders. REPLAGAL and ELAPRASE (both Takeda) address lysosomal storage disorders. BioMarin's portfolio includes VIMIZIM (galipase), NAGLAZYME (galsulfase), and BRINEURA (cerliponase alfa), all targeting different lysosomal storage diseases. Ultragenyx's MEPSEVII (vestronidase alfa) addresses mucopolysaccharidosis VII. Other approved therapies include RAVICTI (sodium phenylbutyrate, Teva), GIVLAARI and OXLUMO (Lacuna Pharma), and PROHIPPUR (MAIA Biotechnology). Asfotase alfa's competitive position is differentiated by its specific mechanism—direct enzyme replacement for alkaline phosphatase deficiency—and its early approval timeline (Japan 2015). The primary competitive challenge is not direct head-to-head competition but rather the clinical management of immune responses that can develop during long-term enzyme replacement therapy, which the RESTORE trial directly addresses. This positions Alexion's immunosuppressive strategy as a potential clinical and commercial differentiator in extending treatment durability.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| SEPHIENCE | PTC THERAPEUTICS, INC. | — | approved |
| PALYNZIQ | BioMarin Pharmaceutical Australia Pty Ltd | — | approved |
| REPLAGAL | Takeda | — | approved |
| MEPSEVII | Ultragenyx UK Limited | — | approved |
| BRINEURA | BioMarin Pharmaceutical Australia Pty Ltd | — | approved |
| RAVICTI | Teva Pharma GmbH | — | approved |
| ELAPRASE | Takeda | — | approved |
| VIMIZIM | BioMarin Pharmaceutical Australia Pty Ltd | — | approved |
| GIVLAARI | Lacuna Pharma Pty Ltd | — | approved |
| OXLUMO | Lacuna Pharma Pty Ltd | — | approved |
| NAGLAZYME | BioMarin Pharmaceutical Australia Pty Ltd | — | approved |
| PROHIPPUR | MAIA Biotechnology | — | approved |
| SETRUSUMAB | — | Sclerostin inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Union: STRENSIQ received marketing authorization on 16 February 2026 (EMEA/H/C/003794) under the centralized procedure, with Alexion Europe SAS as the marketing authorization holder.
United States: Approved via Biologics License Application (BLA 125513) sponsored by Alexion Pharmaceuticals. Specific approval date not disclosed in available facts.
Japan: Approved July 2015 by the Pharmaceuticals and Medical Devices Agency (PMDA), representing the first major market approval for asfotase alfa.
China (NMPA): Regulatory status not yet disclosed.
Patent Status: Not yet disclosed.
Expected Loss of Exclusivity: Not yet disclosed.
Asfotase alfa is used to treat hypophosphatasia, a rare genetic disorder caused by deficiency of alkaline phosphatase enzyme, leading to defective bone mineralization, dental abnormalities, and metabolic complications.
Asfotase alfa is a recombinant human alkaline phosphatase that replaces the deficient enzyme, restoring enzymatic capacity to hydrolyze inorganic pyrophosphate and pyridoxal-5-phosphate, thereby normalizing bone mineralization.
Yes, asfotase alfa is approved in Japan (July 2015), the United States (BLA 125513), and the European Union (February 2026, EMEA/H/C/003794).
Alexion Europe SAS is the sponsor and marketing authorization holder for STRENSIQ in the European Union; Alexion Pharmaceuticals holds the U.S. BLA.
Asfotase alfa is administered by injection, available in both subcutaneous and intravenous formulations.
RESTORE (NCT 2022-502793-17-00) is an open-label prospective study investigating immunosuppressive therapies to mitigate immune-mediated loss of therapeutic response to asfotase alfa in hypophosphatasia patients.
Long-term enzyme replacement therapy can trigger development of neutralizing antibodies that reduce drug efficacy over time, limiting therapeutic durability and requiring management strategies.
Hypophosphatasia is a rare inherited metabolic disorder caused by mutations in the alkaline phosphatase gene (ALPL), resulting in enzyme deficiency, abnormal bone mineralization, dental problems, and in severe cases, respiratory compromise.
Asfotase alfa is classified under Alimentary tract and metabolism (ATC A16) as an enzyme replacement therapy.
Competitors in the rare metabolic disease space include SEPHIENCE (PTC Therapeutics), PALYNZIQ (BioMarin), REPLAGAL and ELAPRASE (Takeda), VIMIZIM and NAGLAZYME (BioMarin), BRINEURA (BioMarin), MEPSEVII (Ultragenyx), RAVICTI (Teva), GIVLAARI and OXLUMO (Lacuna Pharma), and PROHIPPUR (MAIA Biotechnology).
Asfotase alfa was first approved in Japan in July 2015, followed by approvals in the United States and European Union.
Asfotase alfa is approved and active in clinical use; current development focus is the RESTORE trial investigating immunosuppressive co-therapies to improve long-term treatment durability.
Regulatory status in China (NMPA) is not yet disclosed in available information.
Asfotase alfa targets patients with hypophosphatasia across all age groups, from severe infantile forms to milder adult-onset presentations, though the total patient population is small due to the rarity of the disease.
The primary expected milestone is data readout from the RESTORE trial (NCT 2022-502793-17-00) investigating immunosuppressive strategies to maintain therapeutic response; additional milestones may include regulatory submissions in other markets.
Patent status for asfotase alfa is not yet disclosed in available information.
AA-HPP-407 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Alexion's focus on the RESTORE trial reflects a sophisticated understanding of a critical limitation in enzyme replacement therapy—the development of neutralizing antibodies that reduce therapeutic efficacy over time. By proactively investigating immunosuppressive co-therapies, Alexion is positioning asfotase alfa for improved long-term outcomes and potentially expanded patient eligibility (e.g., patients who previously developed antibody-mediated loss of response).
Competitive Implications: Success in the RESTORE trial could establish a clinical and commercial advantage over other enzyme replacement therapies by demonstrating durable therapeutic response. This could influence treatment guidelines and payer coverage decisions, particularly in markets with high penetration of long-term biologic therapy.
Clinical Catalysts: Primary near-term catalyst is RESTORE trial data readout, which could support label expansion or revised treatment protocols. Secondary catalysts include potential regulatory submissions in China (NMPA) and other emerging markets, and real-world evidence studies demonstrating durability advantages.
Market Dynamics: Hypophosphatasia remains a small patient population, but the rarity and severity of the disease support premium pricing. The competitive set includes multiple rare disease therapies, but asfotase alfa's unique mechanism and early approval history provide market position stability. Long-term market growth depends on diagnosis improvement (many cases remain undiagnosed) and durability of therapeutic response.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.